<s id="wsj_0023.1"> 22
3 	 0 	 N/N 	 1 	 Co. F.H.
3 	 1 	 N/N 	 1 	 Co. Faulding
3 	 2 	 N/N 	 1 	 Co. &
3 	 10 	 (S[dcl]\NP)/S[dcl] 	 1 	 Co. said
8 	 5 	 NP[nb]/N 	 1 	 company an
8 	 6 	 N/N 	 1 	 company Australian
8 	 7 	 N/N 	 1 	 company pharmaceuticals
8 	 10 	 (S[dcl]\NP)/S[dcl] 	 1 	 company said
14 	 11 	 NP[nb]/N 	 1 	 affiliate its
14 	 12 	 N/N 	 1 	 affiliate Moleculon
14 	 13 	 N/N 	 1 	 affiliate Inc.
14 	 15 	 ((S[dcl]\NP)/PP)/NP 	 1 	 affiliate acquired
15 	 10 	 (S[dcl]\NP)/S[dcl] 	 2 	 acquired said
17 	 15 	 ((S[dcl]\NP)/PP)/NP 	 3 	 Inc. acquired
17 	 16 	 N/N 	 1 	 Inc. Kalipharma
18 	 15 	 ((S[dcl]\NP)/PP)/NP 	 2 	 for acquired
19 	 18 	 PP/NP 	 1 	 $ for
21 	 19 	 N/N[num] 	 1 	 million $
21 	 20 	 N/N 	 1 	 million 23
<\s>
<s id="wsj_0023.2"> 14
0 	 1 	 (S[dcl]\NP)/NP 	 1 	 Kalipharma is
4 	 3 	 (N/N)/(N/N) 	 2 	 Jersey-based New
6 	 1 	 (S[dcl]\NP)/NP 	 2 	 concern is
6 	 2 	 NP[nb]/N 	 1 	 concern a
6 	 4 	 N/N 	 1 	 concern Jersey-based
6 	 5 	 N/N 	 1 	 concern pharmaceuticals
6 	 7 	 (NP\NP)/(S[dcl]\NP) 	 1 	 concern that
6 	 8 	 (S[dcl]\NP)/NP 	 1 	 concern sells <XB>
8 	 7 	 (NP\NP)/(S[dcl]\NP) 	 2 	 sells that
8 	 10 	 ((S\NP)\(S\NP))/NP 	 2 	 sells under
9 	 8 	 (S[dcl]\NP)/NP 	 2 	 products sells
13 	 10 	 ((S\NP)\(S\NP))/NP 	 3 	 label under
13 	 11 	 NP[nb]/N 	 1 	 label the
13 	 12 	 N/N 	 1 	 label Purepac
<\s>
<s id="wsj_0023.3"> 21
0 	 1 	 (S[dcl]\NP)/S[dcl] 	 1 	 Faulding said
2 	 3 	 (S[dcl]\NP)/NP 	 1 	 it owns
2 	 12 	 (S[dcl]\NP)/NP 	 1 	 it has <XU>
3 	 1 	 (S[dcl]\NP)/S[dcl] 	 2 	 owns said
5 	 3 	 (S[dcl]\NP)/NP 	 2 	 % owns
5 	 4 	 N/N 	 1 	 % 33
5 	 6 	 (NP\NP)/NP 	 1 	 % of
7 	 8 	 (NP[nb]/N)\NP 	 2 	 Moleculon 's
10 	 6 	 (NP\NP)/NP 	 2 	 stock of
10 	 8 	 (NP[nb]/N)\NP 	 1 	 stock 's
10 	 9 	 N/N 	 1 	 stock voting
12 	 1 	 (S[dcl]\NP)/S[dcl] 	 2 	 has said
14 	 12 	 (S[dcl]\NP)/NP 	 2 	 agreement has
14 	 13 	 NP[nb]/N 	 1 	 agreement an
14 	 16 	 (S[b]\NP)/NP 	 1 	 agreement acquire <XB>
16 	 15 	 (S[to]\NP)/(S[b]\NP) 	 2 	 acquire to
20 	 16 	 (S[b]\NP)/NP 	 2 	 % acquire
20 	 17 	 NP[nb]/N 	 1 	 % an
20 	 18 	 N/N 	 1 	 % additional
20 	 19 	 N/N 	 1 	 % 19
<\s>
<s id="wsj_0023.4"> 27
1 	 0 	 NP[nb]/N 	 1 	 stake That
1 	 4 	 (NP\NP)/NP 	 1 	 stake with
1 	 11 	 ((S[dcl]\NP)/NP)/NP 	 1 	 stake gives
4 	 3 	 (NP\NP)/(NP\NP) 	 2 	 with together
9 	 4 	 (NP\NP)/NP 	 2 	 holdings with
9 	 5 	 NP[nb]/N 	 1 	 holdings its
9 	 6 	 N/N 	 1 	 holdings convertible
9 	 7 	 N/N 	 1 	 holdings preferred
9 	 8 	 N/N 	 1 	 holdings stock
12 	 11 	 ((S[dcl]\NP)/NP)/NP 	 3 	 Faulding gives
14 	 11 	 ((S[dcl]\NP)/NP)/NP 	 2 	 right gives
14 	 13 	 NP[nb]/N 	 1 	 right the
14 	 16 	 (S[b]\NP)/NP 	 1 	 right increase <XB>
16 	 15 	 (S[to]\NP)/(S[b]\NP) 	 2 	 increase to
16 	 19 	 ((S\NP)\(S\NP))/NP 	 2 	 increase to
18 	 16 	 (S[b]\NP)/NP 	 2 	 interest increase
18 	 17 	 NP[nb]/N 	 1 	 interest its
21 	 19 	 ((S\NP)\(S\NP))/NP 	 3 	 % to
21 	 20 	 N/N 	 1 	 % 70
21 	 22 	 (NP\NP)/NP 	 1 	 % of
23 	 24 	 (NP[nb]/N)\NP 	 2 	 Moleculon 's
26 	 22 	 (NP\NP)/NP 	 2 	 stock of
26 	 24 	 (NP[nb]/N)\NP 	 1 	 stock 's
26 	 25 	 N/N 	 1 	 stock voting
<\s>
